Abstract
Introduction
Prediabetes is a metabolic state that frequently precedes overt type 2 diabetes mellitus (T2DM) and is associated with an increased risk of micro- and macrovascular complications. Lifestyle modification remains the cornerstone of management, and several pharmacological agents, including metformin, pioglitazone, acarbose and glucagon-like peptide−1 receptor agonists (GLP-1 RAs), have demonstrated efficacy in delaying progression to T2DM. Sodium–glucose cotransporter 2 (SGLT2) inhibitors (often referred to as gliflozins) are increasingly being investigated in this context. The aim of this review is to summarise current evidence regarding the use of SGLT2 inhibitors in adults with prediabetes and to discuss the arguments for and against their routine clinical use.
Methods
A narrative review of publications retrieved from the PubMed database, addressing the role of SGLT2 inhibitors in prediabetes, was performed. Original studies, meta-analyses, systematic reviews and high-quality narrative reviews up to February 2026 were considered for inclusion.
Results
Multiple studies have demonstrated that SGLT2 inhibitors improve insulin sensitivity, promote modest weight reduction, lower blood pressure and exert favourable effects on hepatic lipid metabolism. Two contemporary meta-analyses confirm that SGLT2 inhibitors reduce the incidence of new-onset T2DM in adults with prediabetes who also have heart failure or chronic kidney disease (CKD), with relative risk reductions of approximately 19–21%. This drug class is generally well tolerated, although it is associated with increased risk of genitourinary infections and rare but serious euglycaemic diabetic ketoacidosis.
Conclusions
SGLT2 inhibitors appear to be a promising class of drugs for the prevention of T2DM, particularly in high-risk populations with concomitant cardiovascular or renal disease. However, dedicated randomised controlled trials in prediabetes—with adequate follow-up and washout periods—are necessary before routine use can be recommended. Current 2026 guidelines do not yet endorse SGLT2 inhibitors as a preventive therapy for prediabetes outside the indications of heart failure and CKD.
Keywords: Cardiovascular risk, Diabetes prevention, Flozins, Insulin resistance, MASLD, Prediabetes, SGLT2 inhibitors
Plain Language Summary
About one in eight adults around the world has prediabetes. Without action, many of these people will go on to develop type 2 diabetes. Eating a healthier diet, increasing physical activity and losing weight are the best ways to reduce this risk. Some medicines can also help. A class of medicines called SGLT2 (sodium–glucose cotransporter 2) inhibitors are already widely used in people who have type 2 diabetes, heart failure or chronic kidney disease. In this article we look at whether SGLT2 inhibitors might also help to prevent type 2 diabetes in people with prediabetes. Research so far shows that SGLT2 inhibitors lower the chance of developing type 2 diabetes by roughly one fifth in people with prediabetes who also have heart failure or kidney disease. They also help patients lose weight, improve insulin sensitivity, lower blood pressure and reduce fat in the liver. Side effects are usually mild and most often involve infections of the urinary or genital tract. Despite these findings, there has not yet been a large clinical trial that was specifically designed to evaluate whether SGLT2 inhibitors can prevent diabetes in people with prediabetes alone. The cost of these medicines and uncertainty about how long they need to be taken are also concerns. For these reasons, current international guidelines do not yet recommend SGLT2 inhibitors purely to prevent diabetes; they are recommended only when the patient also has another condition, such as heart failure or kidney disease, that benefits from this treatment.
Key Summary Points
| Prediabetes affects an estimated 12.0% (impaired glucose tolerance) and 9.2% (impaired fasting glucose) of adults globally according to the 11th edition of the International Diabetes Federation (IDF) Diabetes Atlas, and is associated with substantial cardiometabolic risk |
| Pre-specified and post-hoc analyses of cardiovascular outcome trials suggest that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the incidence of new-onset type 2 diabetes by approximately 19–21% in adults with prediabetes who also have heart failure or chronic kidney disease |
| Beyond preventing diabetes, SGLT2 inhibitors in this population produce modest weight loss, improve insulin sensitivity (including hypothalamic insulin signalling), lower blood pressure, attenuate metabolic dysfunction-associated steatotic liver disease (MASLD) and reduce cardiovascular and renal events |
| Their use is limited by the lack of a dedicated, adequately powered randomised controlled trial in isolated prediabetes, by cost, by uncertainty regarding optimal duration of therapy and by class-specific risks (genitourinary infections, rare euglycaemic ketoacidosis) |
| Current 2026 American Diabetes Association Standards of Care do not endorse SGLT2 inhibitors as first-line preventive therapy for prediabetes outside of established indications (heart failure, atherosclerotic cardiovascular disease, chronic kidney disease) |
Introduction
Prediabetes is defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT) on the 75 g oral glucose tolerance test (OGTT) or elevated glycated haemoglobin (HbA1c) in the range 5.7–6.4% (39–47 mmol/mol) according to the American Diabetes Association [1]. It represents a high-risk state for the development of type 2 diabetes mellitus (T2DM) and is increasingly recognised as an independent cardiovascular risk factor.
The global burden of prediabetes is rising. According to the 11th edition of the International Diabetes Federation (IDF) Diabetes Atlas, the worldwide age-standardised prevalence among adults aged 20–79 years in 2024 was estimated to be 12.0% for IGT and 9.2% for IFG—substantially higher than the corresponding figures of 9.1% and 5.8% reported in the 10th edition in 2021 [2, 3]. The highest prevalence of IGT is observed in South-East Asia, whereas the highest prevalence of IFG is found in North America and the Caribbean [2]. Meta-analytic data reported by Gerstein and colleagues indicate an annual conversion rate to T2DM of approximately 5–10%, with the lowest rates seen in individuals with isolated IGT (4–6%) or isolated IFG (6–9%) and the highest rates (approximately 15–19%) in those with combined IGT and IFG [4, 5].
Beyond the risk of progression to overt T2DM, prediabetes is associated with an increased prevalence of microvascular complications (retinopathy, neuropathy and nephropathy) and macrovascular events such as myocardial infarction, stroke and peripheral arterial disease [6, 7]. A systematic review and meta-analysis by Huang et al. demonstrated that prediabetes is associated with increased cardiovascular morbidity and all-cause mortality compared with normoglycaemia [8].
Lifestyle modification that combines dietary changes with regular physical activity, resulting in body weight reduction, remains the cornerstone of management [9]. However, long-term adherence is difficult and frequently inadequate, prompting interest in pharmacological strategies. Metformin, which was first established as preventive therapy in the Diabetes Prevention Program (DPP), is the most widely used drug for this indication [10]. Other agents with proven efficacy in delaying progression to T2DM include pioglitazone (ACT NOW study), acarbose (STOP-NIDDM study) and liraglutide (SCALE Obesity and Prediabetes study [11–13]. More recently, semaglutide and the dual glucose-dependent insulinotropic polypeptide/glucagon like peptide−1 (GIP/GLP-1) receptor agonist (RA) tirzepatide have shown substantial weight loss and high rates of glycaemic normalisation in adults with obesity and prediabetes in the STEP and SURMOUNT programmes, although these were not designed primarily as diabetes-prevention trials [14, 15].
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a class of oral antihyperglycaemic agents that reduce renal glucose reabsorption and induce glycosuria. They have been shown to confer cardiovascular and renal benefits in patients with T2DM, heart failure (HF)—irrespective of ejection fraction—and chronic kidney disease (CKD) [16–18]. A meta-analysis by Mori et al. that pooled data from over 5500 participants, reported a significantly lower incidence of new-onset T2DM in adults with prediabetes treated with SGLT2 inhibitors compared with placebo, suggesting a potential role in primary prevention of T2DM in high-risk individuals [19]. An updated meta-analysis by Singh et al., incorporating five randomised controlled trials (RCTs) with 6752 participants, confirmed a 19% relative reduction in new-onset diabetes (hazard ratio [HR] 0.81; 95% confidence interval [CI] 0.69–0.94) without statistical heterogeneity [20]. Notably, the pre-specified exploratory analysis of the DAPA-HF trial by Inzucchi et al. demonstrated that, over a median follow-up of 18 months, new-onset diabetes occurred in 4.9% of participants with prediabetes randomised to the SGLT2 inhibitor dapagliflozin compared with 7.1% in the placebo arm [21]. Similar benefits have been reported for the SGLT2 inhibitor empagliflozin, including improvements in body weight, inflammatory markers, insulin resistance and hepatic lipid metabolism [22].
The aim of this article is to analyse the arguments for and against the use of SGLT2 inhibitors in prediabetes and to provide a comprehensive overview of the advantages and limitations of these drugs in everyday clinical practice. Understanding these factors may help clinicians offer more effective, personalised preventive treatment to patients at increased risk of T2DM.
Methods
This article is a narrative review. A comprehensive search of the PubMed database was conducted using the keywords "prediabetes", "diabetes prevention", "SGLT2 inhibitors", "sodium–glucose cotransporter 2 inhibitors" and "flozins", individually and in combination with the Boolean operators AND/OR. The search was last updated in February 2026 and included articles published between January 2007 and February 2026.
All retrieved titles and abstracts were screened independently by the authors. Articles judged to contain relevant information were then assessed in full. Original studies, meta-analyses, systematic reviews and high-quality narrative reviews were considered for inclusion. Articles not published in English, letters to the editor, editorials, conference abstracts and case reports were excluded.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
SGLT2 Inhibitors in Prediabetes
Mechanism of Action
Sodium–glucose cotransporter 2 inhibitors selectively block the SGLT2 molecule in the proximal convoluted tubule of the kidney, thereby reducing renal reabsorption of filtered glucose and inducing glycosuria. The resulting decrease in plasma glucose lowers serum insulin and increases plasma glucagon concentrations [23, 24]. SGLT2 inhibitors also increase tissue insulin sensitivity, attenuate renal cortical inflammation and improve renal tubular oxygenation [25, 26]. Because their mechanism is insulin-independent, the risk of hypoglycaemia is very low when SGLT2 inhibitors are used as monotherapy [27].
At standard therapeutic doses, SGLT2 inhibitors induce urinary loss of approximately 60–90 g of glucose per day, equivalent to roughly 200–300 kcal/day, contributing to a modest but sustained body-weight reduction [28]. Through their osmotic–diuretic effect and natriuresis they also reduce plasma volume, leading to a reduction in systolic and diastolic blood pressure, even in people without diabetes [29]. In large cardiovascular outcome trials (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, EMPEROR-Reduced/Preserved, DAPA-HF, DELIVER), SGLT2 inhibitors have been shown to reduce hospitalisation for heart failure and improve composite cardiovascular outcomes [30, 31]. The cardioprotective action of SGLT2 inhibitors is multifactorial and includes lowering of blood pressure, increased natriuresis and diuresis, attenuation of sympathetic nervous system activity, improved myocardial energetics through ketone utilisation, reduction in oxidative stress and prevention of adverse cardiac remodeling [32].
Potential Benefits in Prediabetes
Improvement of Insulin Sensitivity
Insulin resistance, defined as a reduced tissue response to insulin despite normal or elevated plasma insulin concentrations, is a hallmark of prediabetes [33]. It affects peripheral tissues (skeletal muscle, adipose tissue and the liver) as well as the central nervous system [34]. Hypothalamic insulin signaling plays a key role in the regulation of energy intake, peripheral insulin sensitivity and the distribution of adipose tissue. To date, no pharmacological agent has demonstrated a robust ability to reverse "cerebral" insulin resistance. However, a randomised, double-blind, placebo-controlled phase 2 trial by Kullmann et al. in 40 adults with prediabetes showed that 8 weeks of empagliflozin 25 mg/day restored hypothalamic insulin sensitivity—as assessed by functional magnetic resonance imaging (fMRI) following intranasal insulin administration—and was accompanied by reductions in fasting glycaemia and hepatic fat content [35]. These findings position empagliflozin as one of the first agents to demonstrate modulation of central insulin sensitivity in humans.
Weight Reduction
In a randomised study of 24 adults with prediabetes by Ramírez-Rodríguez et al., dapagliflozin reduced body weight by approximately 3 kg (3.7%) over the study period, compared with 1 kg in the placebo arm [36]. Beneficial effects were also observed on waist circumference, fasting plasma glucose, serum uric acid and indices of insulin resistance. These results are consistent with the broader literature showing that SGLT2 inhibitors produce a sustained weight loss of 2–3 kg in patients with and without diabetes—although this is smaller than that achieved with GLP-1 RAs or with the dual GIP/GLP-1 RA tirzepatide [14, 15].
Cardiovascular Effects
Prediabetes is an independent risk factor for cardiovascular disease, and macrovascular complications may appear before overt diabetes is diagnosed [37]. In a 10-week study in prediabetic ob/ob−/− mice, empagliflozin improved coronary flow velocity reserve (CFVR) and fractional area change (FAC), indicating beneficial effects on both coronary microvascular function and left-ventricular contractility, alongside lower HbA1c, reduced hepatic steatosis and a higher glucagon-to-insulin ratio [38]. These mechanistic findings help explain the cardiovascular benefit observed in large outcome trials. Of particular relevance to prediabetes, the EMPEROR-Preserved and DELIVER trials demonstrated reductions in heart failure hospitalisation independent of baseline glycaemic status, including in patients with prediabetes [16, 39]. The 2026 American Diabetes Association (ADA) Standards of Care explicitly recommend SGLT2 inhibitors as a core pharmacological strategy for cardiovascular and renal risk reduction in adults with T2DM, although this recommendation does not yet extend to prediabetes [40].
Renal Effects
Subclinical kidney injury is detectable in many individuals with prediabetes, and prediabetes itself predicts incident CKD. In the DAPA-CKD trial, dapagliflozin reduced the composite renal endpoint by 39% in patients with CKD with or without T2DM [17]. The EMPA-KIDNEY trial subsequently demonstrated that empagliflozin reduced kidney disease progression or cardiovascular death by 28% in a broad CKD population, again irrespective of diabetes status [41]. A recent SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C) meta-analysis found that among patients without diabetes, SCLT2 inhibitors provided clear benefits in terms of renal function—specifically glomerular filtration rate (GFR) and albuminuria—with a smaller decline in GFR observed [42]. Moreover, using SGLT2 inhibitors can be effective in reducing chronic renal disease in participants with normal urinary albumin levels (according to the DECLARE-TIMI 58 trial) [43]. Although neither trial specifically targeted patients with prediabetes, their results suggest that SGLT2 inhibitors may exert renoprotective effects regardless of the glycemic effect, providing an additional argument for their use in selected high-risk prediabetic individuals.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Following an international multi-society consensus published in 2023, the terminology of fatty liver disease has been revised, with non-alcoholic fatty liver disease (NAFLD) replaced by the term metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic steatohepatitis (NASH) replaced by the term metabolic dysfunction-associated steatohepatitis (MASH) [44]. MASLD is closely linked to insulin resistance, obesity and prediabetes and represents one of the most common comorbidities in this patient population.
Several randomised trials have demonstrated favourable effects of SGLT2 inhibitors on hepatic steatosis and fibrosis [45]. In a randomised, placebo-controlled trial in patients with T2DM and biopsy- or imaging-confirmed steatosis, 24 weeks of empagliflozin treatment reduced liver steatosis and fibrosis, as assessed by transient elastography [46]. Similar benefits were demonstrated in a separate trial of empagliflozin in people with NAFLD/MASLD without diabetes [47]. A pre-clinical study by Hüttl and colleagues showed that empagliflozin 10 mg/kg/day for 8 weeks improved hepatic lipid metabolism in non-obese, prediabetic rats, suggesting that its hepatic benefits precede the onset of overt hyperglycaemia [48]. An updated 2025 meta-analysis of 16 RCTs (11,300 participants) confirmed significant improvements in transient elastography parameters and serum fibrosis markers in patients with MASLD treated with SGLT2 inhibitors [49]. A 2025 large real-world cohort study using the TriNetX database further reported that SGLT2 inhibitor therapy in patients with MASLD was associated with improved long-term survival and a markedly lower rate of progression to advanced liver disease over 10 years of follow-up [50]. Moreover, a study by Abbas found that using SGLT2 inhibitors improved liver enzymes, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) or gamma-glutamyl transferase (GGT), but do not have any significant affect on liver stiffness, triglicerydes or Fibrosis-4 (FIB-4 index. Moreover, SGLT2 inhibitors in non-diabetic cohorts offer key anthropometric benefits (significant reductions in body weight, body mass index (BMI), and waist circumference [51].
Effectiveness and Current Evidence Gaps
Although the pre-specified exploratory analysis of the DAPA-HF trial by Inzucchi et al. demonstrated a 32% relative reduction in the risk of new-onset T2DM in patients with heart failure with reduced ejection fraction (HFrEF) and prediabetes who received dapagliflozin therapy (HR 0.68; 95% CI 0.50–0.94; p = 0.019), approximately 5% of dapagliflozin-treated participants still progressed to T2DM during follow-up [21]. The corresponding subgroup analysis of the results from the EMPEROR-Reduced trial showed a numerically lower—but statistically non-significant—incidence of new-onset T2DM in patients with prediabetes (11.2% with empagliflozin vs. 12.6% with placebo); empagliflozin did not lower HbA1c in the prediabetes or normoglycaemia subgroups [52]. Similarly, in the EMPEROR-Preserved trial, the incidence of new-onset T2DM in the prediabetes subgroup was 12.0% with empagliflozin compared with 14.0% with placebo, again not statistically significant [53]. In the PRE-D randomised trial, 120 adults with prediabetes and overweight or obesity were assigned to one of four arms (dapagliflozin, metformin, interval exercise or control) for 13 weeks). Dapagliflozin produced a small but statistically significant reduction in the mean amplitude of glycaemic excursions (MAGE) of 17.1% (95% CI 0.7–30.8; p = 0.042) compared with the control, but no significant between-group differences were observed in body weight or glucose-induced glucagon levels, and the trial was not powered to detect changes in the incidence of new-onset T2DM [54]. The analysis by Ostrominski et al. considers HF studies, chronic renal disease studies, myocardial infraction studies (DAPA-HF, DELIVER, EMPEROR-Preserved, EMPEROR-Reduced, DAPA-CKD, EMPA-KIDNEY, DAPA-MI) [55]. These authors reported that in HF populations, dapagliflozin reduced the incidence of new-onset T2D by 33% (HR 0.67) when compared to placebo. Also, across the broader cardiorrenal population, SGLT2 inhibitor therapy reduced new-onset T2D diagnoses by 26% (HR 0.74) [55]. Collectively, these findings suggest that the magnitude of the preventive benefit of SGLT2 inhibitors is more pronounced in patients with concomitant cardiovascular or renal disease than in otherwise healthy individuals with isolated prediabetes.
Importantly, no large, adequately powered RCT designed primarily to evaluate diabetes prevention in prediabetes has been completed with SGLT2 inhibitors. Existing evidence largely derives from post-hoc analyses of cardiovascular and renal outcome trials, and the persistence of any benefit after drug discontinuation—a key methodological issue, given that SGLT2 inhibitors may transiently lower glucose readings and "mask" diabetes—remains uncertain [20].
Table 1 summarises the principal RCTs, pre-specified subgroup analyses and meta-analyses that have evaluated the effect of SGLT2 inhibitors on the incidence of new-onset T2DM in adults with prediabetes.
Table 1.
Summary of randomised trials, pre-specified subgroup analyses and meta-analyses evaluating the effect of sodium–glucose cotransporter 2 inhibitors on the incidence of new-onset type 2 diabetes mellitus in adults with prediabetes
| Study (year) | Population | n persons included in study | SGLT2 inhibitor | Outcome/comparison | Effect (95% CI) |
|---|---|---|---|---|---|
| Inzucchi et al., DAPA-HF post-hoc analysis (2021) [21] | HFrEF without baseline diabetes (HbA1c < 6.5%); > 95% of incident T2DM occurred in those with baseline prediabetes | 2605 | Dapagliflozin 10 mg vs placebo | New-onset T2DM 4.9% vs 7.1% over median 18 months | HR 0.68 (0.50–0.94); 32% relative reduction; p = 0.019 |
| Anker et al., EMPEROR-Reduced subgroup analysis (2021) [52] | HFrEF with prediabetes (HbA1c 5.7–6.4%) | 1268 | Empagliflozin 10 mg vs placebo | New-onset T2DM 11.2% vs 12.6% over median 16 months; HbA1c not lowered in the prediabetes subgroup | Not statistically significant |
| Filippatos et al., EMPEROR-Preserved subgroup analysis (2022) [53] | HFmrEF/HFpEF with prediabetes (HbA1c 5.7–6.4%) | ≈1976 | Empagliflozin 10 mg vs placebo | New-onset T2DM 12.0% vs 14.0% over median 26 months | Not statistically significant |
| Mori et al., systematic review and meta-analysis (2023) [19] | Adults with prediabetes (predominantly HF or CKD populations); 4 RCTs pooled | 5655 | SGLT2 inhibitors (dapagliflozin, empagliflozin) vs placebo | New-onset T2DM (pooled) | RR 0.79 (0.68–0.93); approx. 21% relative reduction |
| Singh et al., updated meta-analysis (2023) [20] | Adults with prediabetes; 5 RCTs pooled | 6752 | SGLT2 inhibitors vs placebo | New-onset T2DM (pooled) | HR 0.81 (0.69–0.94); approx. 19% relative reduction |
| Ostrominski et al., meta-analysis [55] | Participants with heart failure but without diabetes | 5623 | dapagliflozin vs placebo | New-onset T2DM | Dapagliflozin reduced the incidence of new-onset diabetes by 33% |
| Færch et al., PRE-D trial (2021) [54] | Prediabetes (HbA1c 5.7–6.4%) with overweight or obesity (BMI ≥ 25 kg/m2); open-label | 120 | Dapagliflozin 10 mg vs metformin 1700 mg vs interval exercise vs control | Change in MAGE at 13 weeks (primary); secondary cardiometabolic markers; not powered for new-onset T2DM | Dapagliflozin reduced MAGE by 17.1% (0.7–30.8) vs control, p = 0.042; no significant effect on body weight or glucagon |
BMI Body mass index, CI confidence interval, CKD chronic kidney disease, HbA1c glycated haemoglobin, HF heart failure, HFmrEF heart failure with mildly reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, HR hazard ratio, MAGE mean amplitude of glycaemic excursions, RCT randomised controlled trial, RR relative risk, SGLT2 sodium–glucose cotransporter 2, T2DM type 2 diabetes mellitus
Potential Limitations and Concerns Regarding SGLT2 Inhibitor Therapy
Cost and Access
The high acquisition cost of SGLT2 inhibitors may limit their widespread preventive use, particularly in low- and middle-income countries. In a 2015 U.S. survey, approximately a quarter of respondents reported that they or a family member had not filled a prescription for SGLT2 inhibitors because of cost [56]. SGLT2 inhibitors are currently relatively expensive, and patients with prediabetes typically do not meet reimbursement criteria. However, the long-term economic burden associated with T2DM and its complications substantially outweighs the cost of effective prevention, suggesting that cost-effectiveness analyses of SGLT2 inhibitors for diabetes prevention warrant further study, ideally informed by local epidemiology and healthcare systems [57]. Morton et al. found that SGLT2 inhibitor use among patients with T2DM was more cost-effective than GLP1 analogues when only cardiovascular and renal benefits were considered [58]. Generic dapagliflozin and empagliflozin formulations, which are expected to become available in several European markets between 2026 and 2028, may improve affordability.
Duration of Therapy and Monitoring
The optimal duration of SGLT2 inhibitor therapy for diabetes prevention has not been established. It is equally unclear how the effects of therapy should be monitored—whether through repeated fasting glucose measurement, OGTT, HbA1c or anthropometric parameters such as body weight, BMI and waist circumference. Most published studies have used follow-up periods of approximately 1–2 years [59–61], and the consequences of long-term (> 5-year) use in patients who do not have diabetes are not known. Safety considerations must therefore be central to any decision regarding prolonged therapy in this population.
Adverse Effects
In patients with T2DM, SGLT2 inhibitors are associated with an increased risk of genitourinary infections, particularly mycotic genital infections and uncomplicated urinary tract infections [62]. The risk of severe events such as pyelonephritis, urosepsis or hospitalisation for infection is not significantly higher than with comparator antihyperglycaemic agents [63]. Similar adverse events would be expected in individuals with prediabetes due to the same mechanism, namely, drug-induced glycosuria. These side effects are not seen with metformin or pioglitazone, which represent established alternatives for diabetes prevention.
A rare but serious adverse event is euglycaemic diabetic ketoacidosis (euDKA), which is characterised by metabolic acidosis and ketosis with normal or only mildly elevated blood glucose [64]. EuDKA most commonly occurs in the context of acute illness, prolonged fasting, low-carbohydrate diets, surgery or alcohol consumption, and the resulting absence of hyperglycaemia can delay recognition and treatment [65]. The absolute risk in patients with T2DM is low (< 0.2% per year), and the risk in individuals with prediabetes—who retain endogenous insulin secretion—is presumed to be even lower, but it is not zero. Initial reports of an increased risk of lower-limb amputation and bone fractures with canagliflozin (CANVAS Programme clinical trials) have not been replicated in subsequent trials and pharmacoepidemiological studies and are no longer considered a class effect [66]. In their study, Ostrominski et al. also found that SGLT2 inhibitor therapy can be safely administered to non-diabetic populations without increasing the risk of severe hypoglycemia or diabetic ketoacidosis [55]. Other recognised adverse events include volume depletion (particularly in older adults and those on diuretics) and a transient initial decline in estimated GFR.
Comparison with Other Preventive Therapies
Metformin remains the best-validated pharmacological agent for the prevention of T2DM, based on data from the DPP and its long-term follow-up (Diabetes Prevention Program Outcomes Study [DPPOS]), and is particularly effective in younger adults, in women with prior gestational diabetes and in those with higher BMI [10]. In the DPP, metformin reduced the incidence of diabetes by 31% compared with placebo (but lifestyle intervention reduced the incidence by 58% compared with placebo) over a median follow-up of 2.8 years. The number needed to treat (NNT; i.e. the number of people who would need to be treated with metformin to prevent one case of diabetes), was approximately 14 over 3 years [10]. Metformin was also associated with a mean weight loss of approximately 2.1 kg, compared with only 0.1 kg in the placebo group [10]. The beneficial effects of metformin in individuals with prediabetes were demonstrated in a meta-analysis conducted by Salpeter et al. [67]. This meta-analysis evaluated 31 studies, with the authors reporting that metformin reduced fasting glucose and fasting insulin levels, improved insulin sensitivity, had beneficial effects on lipid profiles and lowered BMI. Metformin use was also shown to reduce the incidence of diabetes by 40% over a mean follow-up period of 1.8 years. The anti-diabetic medication pioglitazone has also been shown to prevent the development of diabetes. In a study by DeFronzo et al., which included more than 600 patients, pioglitazone was associated with a lower incidence of diabetes compared with placebo, with a NNT (defined as the number of people who would need to be treated to prevent one case of diabetes) of 8 over 2.2 years and 18 over 1 year of the trial [11]. Therapy with the alpha-glucosidase inhibitor acarbose is also supported by randomised evidence. In the STOP-NIDDM trial, diabetes occurred in 32% of patients receiving acarbose compared with 42% receiving placebo [12].
GLP-1 RAs—particularly liraglutide 3.0 mg (SCALE Obesity and Prediabetes trial) and semaglutide 2.4 mg (STEP trial)—achieve greater weight loss and higher rates of regression to normoglycaemia than SGLT2 inhibitors [13, 14]. In the approximately 3-year SCALE Obesity and Prediabetes study, diabetes was diagnosed in 2% of the liraglutide group, compared to 6% in the placebo group; liraglutide use was also found to prolong the time to diabetes (time to diagnosis was 2.7-fold longer in the liraglutide group vs placebo) [13]. In the SURMOUNT-1 trial, tirzepatide achieved up to a 22% reduction in body weight and a markedly reduced incidence of T2DM in adults with obesity and prediabetes over 176 weeks [15]. Moreover, after approximately 1.4 years of treatment with tirzepatide, 95.3% of participants in the group with prediabetes had returned to normoglycaemia, compared to 61.9% of participants in the placebo group [15]. SGLT2 inhibitors may be most appropriately positioned as preventive therapy in patients with prediabetes who also have established cardiovascular disease, heart failure, CKD or MASLD—populations in which their multi-organ benefits provide a clear rationale beyond glycaemic prevention alone [21, 41, 68, 69].
Current Guideline Position (2026)
The American Diabetes Association Standards of Care–2026 acknowledge that pharmacotherapy may be considered to prevent or delay progression to T2DM in adults with overweight or obesity at high risk, focusing on weight loss, attenuation of hyperglycaemia and cardiovascular risk reduction [40]. Metformin is specifically recommended in selected high-risk individuals. SGLT2 inhibitors are not currently recommended as first-line preventive therapy in isolated prediabetes; however, in patients with prediabetes who also have HF, atherosclerotic cardiovascular disease or CKD, SGLT2 inhibitors are indicated for the management of those conditions and may simultaneously reduce the incidence of new-onset T2DM as a clinically meaningful secondary benefit [40]. The European Society of Cardiology (ESC) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines adopt a comparable stance.
Conclusions
Sodium–glucose cotransporter 2 inhibitors exert pleiotropic effects such as glycaemic control, weight reduction, improvement in insulin sensitivity, attenuation of MASLD, lowering of blood pressure and cardiovascular and renal protection. Studies indicate that SGLT2 inhibitors reduce the incidence of new-onset T2DM by approximately 19–21% in adults with prediabetes, with the most consistent benefits observed in those with concomitant HF or CKD. This class of medication has a generally favourable safety profile, although the increased risk of genitourinary infections and the rare possibility of euglycaemic diabetic ketoacidosis must be considered.
Acknowledgments
Medical Writing/Editorial Assistance
No editorial assistance was used.
Author Contributions
Conceptualisation: Anna C. Owczarczyk-Durma, Leszek Czupryniak. Methodology: Anna C. Owczarczyk-Durma, Monika Blicharska, Leszek Czupryniak. Writing—original draft preparation: Anna C. Owczarczyk-Durma, Monika Blicharska. Writing—review and editing: Anna C. Owczarczyk-Durma, Monika Blicharska and Leszek Czupryniak. Supervision: Leszek Czupryniak. All authors have read and agreed to the published version of the manuscript.
Funding
No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Declarations
Conflict of interest
Anna C. Owczarczyk-Durma, Monika Blicharska and Leszek Czupryniak have nothing to disclose.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
References
- 1.American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. [DOI] [PMC free article] [PubMed]
- 2.Genitsaridi I, Salpea P, Salim A, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2024;14(2):149–56. [DOI] [PubMed] [Google Scholar]
- 3.Rooney MR, He JH, Salpea P, et al. Global and regional prediabetes prevalence: updates for 2024 and projections for 2050. Diabetes Care. 2024;48(11):e142–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305–12. [DOI] [PubMed] [Google Scholar]
- 5.Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi KC. Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int. 2017;2017:7839101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zand A, Ibrahim K, Patham B. Prediabetes: why should we care? Methodist Debakey Cardiovasc J. 2018;14(4):289–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–15. [DOI] [PubMed] [Google Scholar]
- 12.Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–7. 10.1016/S0140-6736(02)08905-5. [DOI] [PubMed] [Google Scholar]
- 13.le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409. [DOI] [PubMed] [Google Scholar]
- 14.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. [DOI] [PubMed] [Google Scholar]
- 15.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. [DOI] [PubMed] [Google Scholar]
- 16.Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. [DOI] [PubMed] [Google Scholar]
- 17.Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. [DOI] [PubMed] [Google Scholar]
- 18.Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol. 2023;14:1118848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mori Y, Duru OK, Tuttle KR, et al. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023;108(1):221–31. [DOI] [PubMed] [Google Scholar]
- 20.Singh AK, Singh A, Singh R. New-onset diabetes with sodium-glucose cotransporter-2 inhibitors in prediabetes: an updated meta-analysis and possible mechanisms. Diabetes Metab Syndr. 2023;17(6):102789. [DOI] [PubMed] [Google Scholar]
- 21.Inzucchi SE, Docherty KF, Køber L, et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586–94. [DOI] [PubMed] [Google Scholar]
- 22.Hossain MF, Khan NA, Rahman A, et al. Empagliflozin ameliorates progression from prediabetes to diabetes and improves hepatic lipid metabolism: a systematic review. Cureus. 2022;14(8):e28367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Alatrach M, Laichuthai N, Martinez R, et al. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes. 2020;69(4):681–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Investig. 2014;124(2):509–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016;39(11):2036–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Veelen A, Andriessen C, Op den Kamp Y, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023;140:155396. [DOI] [PubMed] [Google Scholar]
- 29.Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. [DOI] [PubMed] [Google Scholar]
- 31.Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. [DOI] [PubMed] [Google Scholar]
- 32.Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mayans L. Metabolic syndrome: insulin resistance and prediabetes. FP Essent. 2015;435:11–6. [PubMed] [Google Scholar]
- 34.Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15–37. 10.4093/dmj.2021.0280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kullmann S, Hummel J, Wagner R, et al. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care. 2022;45(2):398–406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E. Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes. 2020;128(8):506–11. [DOI] [PubMed] [Google Scholar]
- 37.Cosic V, Jakab J, Pravecek MK, Miskic B. The importance of prediabetes screening in the prevention of cardiovascular disease. Med Arch. 2023;77(2):97–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Adingupu DD, Göpel SO, Grönros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice. Cardiovasc Diabetol. 2019;18(1):16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98. [DOI] [PubMed] [Google Scholar]
- 40.American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities; 10. Cardiovascular disease and risk management: standards of care in diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S50–216. [Google Scholar]
- 41.The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2026;335(3):233–44. 10.1001/jama.2025.20834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic kidney disease and risk management: standards of care in diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–60. 10.2337/dc26-S011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Adv Exp Med Biol. 2021;1307:213–30. [DOI] [PubMed] [Google Scholar]
- 46.Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12(3):843–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37(11):4697–708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Hüttl M, Markova I, Miklankova D, et al. In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia. Int J Mol Sci. 2021;22(21):11513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Yang L, Ruan J, Fang Y, Xu A. Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. Front Med. 2025;12:1667823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Suki M, Imam A, Amer J, et al. SGLT2 inhibitors in MASLD (metabolic dysfunction-associated steatotic liver disease) associated with sustained hepatic benefits, besides the cardiometabolic. Pharmaceuticals. 2025;18(8):1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Abbas MS, Dandamudi M, Rehman T, et al. Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Diabetes Metab Disord. 2025;24(2):285. 10.1007/s40200-025-01797-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Anker SD, Butler J, Filippatos G, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial. Circulation. 2021;143(4):337–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146(9):676–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Færch K, Blond MB, Bruhn L, et al. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D trial): a multi-arm, randomised, controlled trial. Diabetologia. 2021;64(1):42–55. [DOI] [PubMed] [Google Scholar]
- 55.Ostrominski JW, Højbjerg Lassen MC, Claggett BL, et al. Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. Eur Heart J. 2025. 10.1093/eurheartj/ehae780. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–71. [DOI] [PubMed] [Google Scholar]
- 57.McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab. 2020;22(12):2364–74. 10.1111/dom.14162. [DOI] [PubMed] [Google Scholar]
- 58.Morton JI, Marquina C, Shaw JE, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66(4):642–56. 10.1007/s00125-022-05832-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. [DOI] [PubMed] [Google Scholar]
- 60.McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. [DOI] [PubMed] [Google Scholar]
- 61.Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35. [DOI] [PubMed] [Google Scholar]
- 62.Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines. 2022;9(12):59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42. [DOI] [PubMed] [Google Scholar]
- 65.Ali E, Kamran S, Cheema AAA. SGLT2 inhibitors and the underrecognized risk of euglycemic diabetic ketoacidosis: a clinical call for vigilance. Ann Med Surg. 2025;87(11):e3890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(2):149–57. 10.1016/j.amjmed.2007.09.016. [DOI] [PubMed] [Google Scholar]
- 68.Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. 10.1056/NEJMoa2024816. [DOI] [PubMed] [Google Scholar]
- 69.Samaan K, Wagdy K. DELIVER: extending the benefits of SGLT-2 inhibitors. Glob Cardiol Sci Pract. 2023;2023(3):e202321. 10.21542/gcsp.2023.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
